本文關(guān)鍵詞： 型艾滋病病毒 高效抗反轉(zhuǎn)錄病毒治療 齊多夫定 司坦夫定　出處：《中國(guó)艾滋病性病》2015年07期 　論文類型：期刊論文

【摘要】：目的評(píng)價(jià)司坦夫定(D4T)治療6個(gè)月后,轉(zhuǎn)換為齊多夫定(AZT)為主的高效抗反轉(zhuǎn)錄病毒治療(HAART)的療效和安全性。方法 2009年1月到2011年11月,募集201例初治1型艾滋病病毒(HIV-1)感染者,給予D4T治療6個(gè)月后轉(zhuǎn)換為AZT為主的HAART,隨訪96周,并對(duì)免疫學(xué)應(yīng)答和病毒學(xué)應(yīng)答進(jìn)行評(píng)估以及不良反應(yīng)監(jiān)測(cè)。結(jié)果 HAART 96周時(shí),病毒載量(VL)下降(3.20土0.91)lg拷貝/mL;VL40拷貝/mL的比例為94.0%,VL400拷貝/mL的比例為99.0%。CD+4T淋巴細(xì)胞從161(83、249)個(gè)/μL[四分?jǐn)?shù)位間距(IQR)]明顯增長(zhǎng)至311(234,446)個(gè)/μL(IQR)(P0.001)。HAART過(guò)程中7.0%(13/185)的病人出現(xiàn)3級(jí)以上中性粒細(xì)胞減少癥,2.2%(4/185)為3級(jí)以上貧血;8.6%(16/185)的病人因嚴(yán)重不良反應(yīng)改換方案或者終止治療,其中貧血占2.2%(4/185),脂肪分布異常2.2%(4/185),中性粒細(xì)胞減少1.6%(3/185),胃腸反應(yīng)1.6%(3/185),其他1.1%(2/185)。結(jié)論 D4T治療6個(gè)月后轉(zhuǎn)換為AZT為主的一線抗病毒治療方案安全且有效,尤其適合用于資源緊缺的地區(qū)。
[Abstract]:Objective to evaluate the efficacy and safety of highly effective antiretroviral therapy (HAART), which was converted to azidovudine (AZT) after 6 months of treatment. Methods from January 2009 to November 2011, 201 patients with newly treated HIV 1 infected with HIV 1 were recruited. HAART, which was converted to AZT after 6 months of D4T therapy, was followed up for 96 weeks, and the immune and virological responses were evaluated and adverse reactions were monitored. The viral load (VLV) dropped 3.20 鹵0.91g / mL / 渭 L / 渭 L / 渭 L / 渭 L / 渭 L / 渭 L of 99.0 / 渭 L / 渭 L / 渭 L / 渭 L of 99.00.CD4T lymphocytes / 渭 L / 渭 L / 渭 L / 渭 L / 渭 L IQRO / 渭 L IQRN P 0.001N / HAART patients with more than 3 grades of neutrophilic granulocytes appeared in the process of ART. Cytopenia 2. 2 / 1855. For grade 3 or more, anemia is 8. 6 percent to 16 / 185.) because of severe adverse reactions, patients change programs or terminate treatment. Anemia accounts for 2.2% of the total, fat distribution is abnormal 2.2%, neutrophilic granulocyte decreases 1.6%, gastrointestinal reaction 1.6% 1855, and other 1.1% 185%. Conclusion D4T is a safe and effective first-line antiviral therapy that converts to AZT after 6 months of treatment, especially in areas where resources are scarce.
【作者單位】： 中國(guó)醫(yī)學(xué)科學(xué)院北京協(xié)和醫(yī)院;
【基金】：十二五國(guó)家重點(diǎn)科技專項(xiàng)(2012ZX10001003)~~
【分類號(hào)】：R512.91

【共引文獻(xiàn)】

相關(guān)期刊論文 前1條

1 Tahereh Ghaziani;Hossein Sendi;Saeid Shahraz;Philippe Zamor;Herbert L Bonkovsky;;Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome[J];World Journal of Gastroenterology;2014年39期

相關(guān)碩士學(xué)位論文 前1條

1 李青艷;接受抗逆轉(zhuǎn)錄病毒治療的艾滋病患者脂肪營(yíng)養(yǎng)不良的現(xiàn)況研究[D];安徽醫(yī)科大學(xué);2013年

【相似文獻(xiàn)】

相關(guān)期刊論文 前2條

1 趙紅衛(wèi);抗HIV新藥司坦夫定[J];國(guó)外醫(yī)學(xué).藥學(xué)分冊(cè);1997年04期

2 ;[J];;年期

，

本文編號(hào)：1497651